Science
Two studies in the January issue of Gastroenterology show that subcutaneous golimumab induces and maintains clinical response and remission in patients with moderate-to-severe ulcerative colitis; Dr. Kuemmerle speaks to Dr. Brian G. Feagan
Subcutaneous Golimumab Induces and Maintains Clinical Response and Remission in Patients with Moderate-to-Severe Ulcerative Colitis
Share:
Listens: 0